Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease - PubMed (original) (raw)

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease

N Andreasen et al. Arch Neurol. 1999 Jun.

Abstract

Objectives: To study the diagnostic potential of the 42 amino acid form of beta-amyloid (beta-amyloid(1-42)) in cerebrospinal fluid (CSF) as a biochemical marker for Alzheimer disease (AD), the intra-individual biological variation of CSF-beta-amyloid(1-42) level in patients with AD, and the possible effects of differential binding between beta-amyloid and apolipoprotein E isoforms on CSF-beta-amyloid(1-42) levels.

Design: A 20-month prospective follow-up study.

Setting: Community population-based sample of consecutive patients with AD referred to the Piteå River Valley Hospital, Piteå, Sweden.

Patients: Fifty-three patients with AD (mean +/- SD age, 71.4 +/- 7.4 years) diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria and 21 healthy, age-matched (mean +/- SD age, 68.8 +/- 8.0 years) control subjects.

Main outcome measures: Cerebrospinal fluid beta-amyloid(1-42) level--analyzed using enzyme-linked immunosorbent assay--and severity of dementia--analyzed using the Mini-Mental State Examination.

Results: Mean +/- SD levels of CSF-beta-amyloid(1-42) were decreased (P<.001) in patients with AD (709 +/- 304 pg/mL) compared with controls (1678 +/- 436 pg/mL). Most patients with AD (49 [92%] of 53 patients) had reduced levels (<1130 pg/mL). A highly significant correlation (r = 0.90; P<.001) between baseline and 1-year follow-up CSF-beta-amyloid(1-42) levels was found. There were no significant correlations between CSF-beta-amyloid(1-42) level and duration (r = -0.16) or severity (r = -0.02) of dementia. Low levels were also found in patients with mild dementia (Mini-Mental State Examination score, >25).

Conclusions: The sensitivity of CSF-beta-amyloid(1-42) level as a diagnostic marker for AD is high. The intra-individual biological variation in CSF-beta-amyloid(1-42) level is low. Low CSF-beta-amyloid(1-42) levels are also found in the earlier stages of dementia in patients with AD. These findings suggest that CSF-beta-amyloid(1-42) analyses may be of value in the clinical diagnosis of AD, especially in the early course of the disease, when drug therapy may have the greatest potential of being effective but clinical diagnosis is particularly difficult.

PubMed Disclaimer

Comment in

Cerebrospinal fluid opens a window on Alzheimer disease.
Galasko D. Galasko D. Arch Neurol. 1999 Jun;56(6):655-6. doi: 10.1001/archneur.56.6.655. Arch Neurol. 1999. PMID: 10369301 No abstract available.

Cited by

In vivo detection of beta-amyloid at the nasal cavity and other skull-base sites: a retrospective evaluation of ADNI1/GO.
Kapadia A, Desai P, Dmytriw A, Maralani P, Heyn C, Black S, Symons S; Alzheimer’s Disease Neuroimaging Initiative. Kapadia A, et al. Ann Nucl Med. 2021 Jun;35(6):728-734. doi: 10.1007/s12149-021-01614-7. Epub 2021 Apr 12. Ann Nucl Med. 2021. PMID: 33844185
Biomarkers for the Early Detection and Progression of Alzheimer's Disease.
Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ. Counts SE, et al. Neurotherapeutics. 2017 Jan;14(1):35-53. doi: 10.1007/s13311-016-0481-z. Neurotherapeutics. 2017. PMID: 27738903 Free PMC article. Review.
Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease.
Omar SH, Preddy J. Omar SH, et al. J Pers Med. 2020 Jul 17;10(3):63. doi: 10.3390/jpm10030063. J Pers Med. 2020. PMID: 32708853 Free PMC article. Review.
β-amyloid dynamics in human plasma.
Huang Y, Potter R, Sigurdson W, Kasten T, Connors R, Morris JC, Benzinger T, Mintun M, Ashwood T, Ferm M, Budd SL, Bateman RJ. Huang Y, et al. Arch Neurol. 2012 Dec;69(12):1591-7. doi: 10.1001/archneurol.2012.18107. Arch Neurol. 2012. PMID: 23229043 Free PMC article.
Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of alzheimer's disease.
Karki HP, Jang Y, Jung J, Oh J. Karki HP, et al. J Nanobiotechnology. 2021 Mar 9;19(1):72. doi: 10.1186/s12951-021-00814-7. J Nanobiotechnology. 2021. PMID: 33750392 Free PMC article. Review.

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease - PubMed (original) (raw)